Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 98,734 shares, an increase of 2,262.6% from the November 30th total of 4,179 shares. Based on an average trading volume of 170,340 shares, the short-interest ratio is currently 0.6 days. Based on an average trading volume of 170,340 shares, the short-interest ratio is currently 0.6 days.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on FSNUY shares. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a report on Monday, October 27th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy”.

Fresenius SE & Co. Stock Performance

Shares of FSNUY stock traded up $0.11 during trading on Wednesday, hitting $14.40. 16,185 shares of the stock traded hands, compared to its average volume of 51,310. The company has a quick ratio of 0.99, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The firm’s fifty day moving average price is $14.81 and its 200-day moving average price is $13.68. Fresenius SE & Co. has a 52-week low of $8.58 and a 52-week high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.02. The firm had revenue of $6.29 billion for the quarter, compared to analysts’ expectations of $6.38 billion. Fresenius SE & Co. had a return on equity of 9.72% and a net margin of 5.26%. Analysts anticipate that Fresenius SE & Co. will post 0.79 earnings per share for the current year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.